Thoratec Upgraded to Neutral - Analyst Blog

An image of a tablet with a stock chart on the display
Credit: Shutterstock photo

On Apr 11, we upgraded Thoratec Corp. ( THOR ), a leader in mechanical circulatory assistance devices to Neutral, based on its prospects. The company is expected to report first quarter 2013 results toward the end of Apr.

Why the Upgrade?

Revenues for Thoratec rose 17% year over year to $128 million in the fourth quarter, beating the Zacks Consensus Estimate of $119 million. Its fourth-quarter 2012 adjusted earnings per share of 34 cents narrowly beat the Zacks Consensus Estimates of 33 cents. Thoratec has reported positive earnings surprises in three of the last four quarters with an average surprise of 13.9%.

Over the last 90 days, the Zacks Consensus Estimate for 2013 has advanced by 2.5% to $1.67 while the same for 2014 has inched up 0.5% to $1.98 over the same timeframe.

Thoratec's monopoly in the U.S. market, in the case of the bridge-to-transplant ("BTT") therapy, has come to an end. It followed FDA approval, in November 2012, for Heartware International's (HTWR) Ventricular Assist System as a BTT for patients with end-stage heart failure. Thoratec still enjoys pre-eminence in the U.S. in the Destination Therapy ("DT") market. Thoratec faces no near-term competitive threat in DT as the HeartWare device is not expected to be launched in the near future.

Thoratec has a proven track-record in R&D. The company is currently developing its next generation HeartMate III. Thoratec accomplished first human usage of HeartMate Percutaneous Heart Pump (HeartMate PHP) in Mar 2013. Next generation HeartMate devices under development will be less invasive and easier to implant. However, lack of pipeline visibility and relative lack of milestones represent concerns.

Other Stocks to Consider

Thoratec carries a Zacks Rank #3 (Hold). We are more optimistic about Cepheid ( CPHD ), Cyberonics Inc. ( CYBX ) and Given Imaging Ltd. ( GIVN ), each of which carry a Zacks Rank #1 (Strong Buy) and are expected to do well.

CEPHEID INC (CPHD): Free Stock Analysis Report

CYBERONICS INC (CYBX): Free Stock Analysis Report

GIVEN IMAGING (GIVN): Free Stock Analysis Report

THORATEC CORP (THOR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More